JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by John, L. C.
Right arrow Articles by Kovacs, I. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by John, L. C.
Right arrow Articles by Kovacs, I. B.

The Journal of Thoracic and Cardiovascular Surgery, Vol 105, 816-822, Copyright © 1993 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association


ARTICLES

Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage

LC John, GM Rees and IB Kovacs
Department of Cardiothoracic Surgery, St. Bartholomew's Hospital, West Smithfield, London, England.

The effect of heparin (5 U/ml) on platelet function was examined by hemostatometry in vitro. A wide individual variation of this effect was found in 290 patients who underwent cardiac operations: 8.6% (25) experienced a proaggregatory effect, 58.6% (170) experienced a mild to moderate inhibition of platelet function, and 32.8% (95) experienced a severe inhibition. No significant difference was found among patient characteristics, including antiplatelet medication, in these three subgroups. In vitro measurements correlated significantly with ex vivo measurements, that is, from blood taken after heparinization (p < 0.0001; r = 0.97, n = 15). In 111 patients who underwent cardiac surgical intervention, a significant correlation (p < 0.0001; 0.4 < r < 0.52) was found between preoperative measurements of the degree of inhibition of platelet function by heparin and the total postoperative blood loss after 4, 12, and 18 hours. Similarly, there was a significant difference (p < 0.0001) in the total blood loss at 4, 12, and 18 hours between the subgroups that showed, in vitro, a mild to moderate inhibition of platelet function preoperatively compared with a severe inhibition (713 +/- 43 ml versus 1172 +/- 76 ml at 18 hours). It is concluded that platelet inhibition as a result of heparin varies among patients and appears to be a previously unrecognized etiologic factor in bleeding after cardiopulmonary bypass.


This article has been cited by other articles:


Home page
J CARDIOVASC PHARMACOL THERHome page
M. S. Williams and L. S. Ng'alla
Heparin Therapy Leads to Platelet Activation and Prolongation of PFA-100 Closure Time
Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4): 273 - 280.
[Abstract] [PDF]


Home page
PerfusionHome page
R de Vroege, F te Meerman, L Eijsman, W R Wildevuur, C. R. Wildevuur, and W van Oeveren
Induction and detection of disturbed homeostasis in cardiopulmonary bypass
Perfusion, September 1, 2004; 19(5): 267 - 276.
[Abstract] [PDF]


Home page
Card Surg AdultHome page
R. Salenger, J. S. Gammie, and T. J. Vander Salm
Postoperative Care of Cardiac Surgical Patients
Card. Surg. Adult, January 1, 2003; 2(2003): 439 - 469.
[Full Text]


Home page
Ann. Thorac. Surg.Home page
G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr
Mechanisms and attenuation of hemostatic activation during extracorporeal circulation
Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
K. Kottke-Marchant and S. Sapatnekar
Hemostatic Abnormalities in Cardiopulmonary Bypass: Pathophysiologic and Transfusion Considerations
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 187 - 206.
[Abstract] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
L. Shore-Lesserson
Monitoring the Hematologic Complications of Cardiopulmonary Bypass
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 207 - 216.
[Abstract] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
N. J. Skubas and G. J. Despotis
Optimal Management of Bleeding Complications After Cardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 217 - 228.
[Abstract] [PDF]


Home page
PerfusionHome page
M H Cross
Autotransfusion in cardiac surgery
Perfusion, September 1, 2001; 16(5): 391 - 400.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. J. Despotis and L. T. Goodnough
Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery
Ann. Thorac. Surg., August 1, 2000; 70(2): S20 - 32.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. Nakajima, K. Kawazoe, K. Ishibashi, Y. Kubota, T. Sasaki, H. Izumoto, and T. Nitatori
Reduction of heparin dose is not beneficial to platelet function
Ann. Thorac. Surg., July 1, 2000; 70(1): 186 - 190.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
J. A. Hyde, J. A Chinn, and T. R Graham
Platelets and cardiopulmonary bypass
Perfusion, December 1, 1998; 13(6): 389 - 407.
[PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
E. Belougne-Malfattie, O. Aguejouf, L. Labrousse, and C. Doutremepuich
A Comparison of Heparin and New Anticoagulants for Cardiopulmonary Bypass Surgery
Clinical and Applied Thrombosis/Hemostasis, April 1, 1998; 4(2): 118 - 125.
[Abstract] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
T. Z. Naqvi, P. K. Shah, P. A. Ivey, M. D. Molloy, P. Linn, M. Linker-Israeli, B. Cercek, and S. Kaul
Therapeutic Concentrations of Heparin Augment Platelet Activation at the Time of Coronary Angiography
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 91 - 101.
[Abstract] [PDF]


Home page
Clin. Chem.Home page
G. J. Despotis, J. H. Joist, and L. T. Goodnough
Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes
Clin. Chem., September 1, 1997; 43(9): 1684 - 1696.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. H. Kuitunen, L. J. Heikkila, and M. T. Salmenpera
Cardiopulmonary Bypass With Heparin-Coated Circuits and Reduced Systemic Anticoagulation
Ann. Thorac. Surg., February 1, 1997; 63(2): 438 - 444.
[Abstract] [Full Text]


Home page
BMJHome page
L. C H John
"Phlebomania Hancocksia": prevalence of a previously undescribed psychomotor disturbance
BMJ, December 21, 1996; 313(7072): 1620 - 1620.
[Full Text]


Home page
Ann. Thorac. Surg.Home page
A. Wahba, G. Rothe, G. Schmitz, D. E. Birnbaum, S. F. Khuri, C. R. Valeri, J. Loscalzo, and A. D. Michelson
Heparin Effect on Platelets and Fibrinolysis
Ann. Thorac. Surg., May 1, 1996; 61(5): 1590 - 1591.
[Full Text]


Home page
Ann. Thorac. Surg.Home page
E. Ovrum, T. E. Mollnes, E. Fosse, E. A. Holen, G. Tangen, M.-A. L. Ringdal, and V. Videm
High and Low Heparin Dose With Heparin-Coated Cardiopulmonary Bypass: Activation of Complement and Granulocytes
Ann. Thorac. Surg., December 1, 1995; 60(6): 1755 - 1761.
[Abstract] [Full Text]


Home page
Ann. Thorac. Surg.Home page
S. F. Khuri, C. R. Valeri, J. Loscalzo, M. J. Weinstein, V. Birjiniuk, N. A. Healey, H. MacGregor, M. Doursounian, and M. A. Zolkewitz
Heparin Causes Platelet Dysfunction and Induces Fibrinolysis Before Cardiopulmonary Bypass
Ann. Thorac. Surg., October 1, 1995; 60(4): 1008 - 1014.
[Abstract] [Full Text]


Home page
Ann. Thorac. Surg.Home page
O. Gil, J. C. Catala, A. L. Fernandez, J. A. Montero, D. Luna, O. Tovar, M. Tonz, T. Mihaljevic, L. K. von Segesser, and M. I. Turina
Normothermia, Hypothermia, and Postoperative Bleeding
Ann. Thorac. Surg., October 1, 1995; 60(4): 1160 - 1161.
[Full Text]


Home page
Ann. Thorac. Surg.Home page
E. Ovrum, E. A. Holen, G. Tangen, F. Brosstad, M. Abdelnoor, M.-A. L. Ringdal, R. Oystese, and R. Istad
Completely Heparinized Cardiopulmonary Bypass and Reduced Systemic Heparin: Clinical and Hemostatic Effects
Ann. Thorac. Surg., August 1, 1995; 60(2): 365 - 371.
[Abstract] [Full Text]


Home page
J. Thorac. Cardiovasc. Surg.Home page
G. J. Despotis, J. H. Joist, C. W. Hogue Jr., A. Alsoufiev, K. Kater, L. T. Goodnough, S. A. Santoro, E. Spitznagel, M. Rosenblum, and D. G. Lappas
The impact of heparin concentration and activated clotting time monitoring on blood conservation: A prospective, randomized evaluation in patients undergoing cardiac operation
J. Thorac. Cardiovasc. Surg., July 1, 1995; 110(1): 46 - 54.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1993 by The American Association for Thoracic Surgery.